Claire Beveridge, MD
Gastroenterology · Cleveland, OHNPI 1649664608
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,755 of the $6,677 with a category attached, or 86.2%. 8 manufacturers reported payments, led by Sanofi at 47.6% of the total. 2025 is the largest year on record at $3,113, 3.1 times the $1,000 reported in 2021.
Across 36 payments — averaging $185.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Lucid Diagnostics Inc.$1K
- Regeneron Healthcare Solutions, Inc.$279
- Phathom Pharmaceuticals, Inc.$96
- Johnson & Johnson$19
- plus $32 from 2 others
Across 1 payment — averaging $24,600 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$25K
What the payments were for
- Consulting fees$5,75586%
- Food & beverage$92214%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 11 | $3,177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $2,075 |
| Lucid Diagnostics Inc. | 1 | $1,000 |
| Regeneron Healthcare Solutions, Inc. | 8 | $279 |
| Phathom Pharmaceuticals, Inc. | 8 | $96 |
| Johnson & Johnson | 1 | $19 |
| AbbVie | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EOHILIA$1,988
- ESOCHECK CCD CELL COLLECTION DEVICE$1,000
How this compares
$6,677 in reported general payments places this provider in the 70th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 12 | $93,658 |
| Omeprazole | 118 | $1,942 |
| Esomeprazole Magnesium | 13 | $489 |
| Pantoprazole Sodium | 21 | $393 |
| Famotidine | 21 | $259 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Cleveland
- Pierre GholamCleveland$1.6M
- Florian RiederCleveland$396K
- Stanley CohenCleveland$338K
- Taha QaziCleveland$307K
- Vu NguyenCleveland$145K
- Benjamin CohenCleveland$144K
- Imad AsaadCleveland$141K
- Ronnie FassCleveland$123K
- Amit BhattCleveland$118K
- Anjana PillaiCleveland$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.